Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development NEW YORK , March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused

Mar 04, 2024

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Record DANYELZA® net product revenues of $ 23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42 % and 71%, respectively Cash and cash equivalents of $ 78.6 million as of December 31, 2023 ; Reiterate anticipated cash runway into 2027 Management announces full year 2024

Feb 29, 2024

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

NEW YORK , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023 , on Thursday, February 29, 2024 , after the close of the U.S.

Feb 16, 2024

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK , Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Jan 02, 2024

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 24 of 24